For example, we have previously shown that genes involved in Pharm-GKB derived ACE-inhibitor pathway show altered multivariate gene expression patterns in the kidneys of patients with renal disease which is consistent with their levels of tubular atrophy/interstitial fibrosis (Zapala and Schork, 2006). This evidence concerns the gene ACE and kidney disorder.